Healthcare ❯ Pharmaceuticals ❯ Drug Development ❯ GLP-1 Treatments

Eli Lilly and Company

Analyst Warns Eli Lilly’s GLP-1 Lead Is Fading as CFRA Lifts Rating to Buy

New views pit strong tirzepatide momentum against rising GLP-1 competition.